552 J.M. Walker and A.G. Hohmann
noid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther
301:1020–1024
Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003) The neuronal distribution
of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience
120:155–162
Prusakiewicz JJ, Kingsley PJ, Kozak KR, Marnett LJ (2002) Selective oxygenation of N-
arachidonylglycine by cyclooxygenase-2. Biochem Biophys Res Commun 296:612–617
Puffenbarger RA, Boothe AC, Cabral GA (2000) Cannabinoids inhibit LPS-inducible cy-
tokine mRNA expression in rat microglial cells. Glia 29:58–69
Puig S, Sorkin LS (1996) Formalin-evoked activity in identified primary afferent fibers:
systemic lidocaine suppresses phase-2 activity. Pain 64:345–355
Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan
TP Jr (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2
cannabinoid receptors. Anesthesiology 99:955–960
Raft D, Gregg J, Ghia J, Harris L (1977) Effects of intravenous tetrahydrocannabinol on
experimental and surgical pain. Psychological correlates of the analgesic response. Clin
Pharmacol Ther 21:26–33
Reynolds DV (1969) Surgery in the rat during electrical analgesia induced by focal brain
stimulation. Science 164:444–445
Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and pe-
ripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty
Acids 66:243–256
Richardson JD, Aanonsen L, Hargreaves KM (1997) SR 141716A, a cannabinoid receptor
antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3–R4
Richardson JD, Aanonsen L, Hargreaves KM (1998a) Antihyperalgesic effects of spinal
cannabinoids. Eur J Pharmacol 345:145–153
Richardson JD, Aanonsen L, Hargreaves KM (1998b) Hypoactivity of the spinal cannabinoid
system results in NMDA-dependent hyperalgesia. J Neurosci 18:451–457
Richardson JD, Kilo S, Hargreaves KM (1998c) Cannabinoids reduce hyperalgesia and
inflammation via interaction with peripheral CB1 receptors. Pain 75:111–119
Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan
DJ, Scott RH (2001a) Actions of cannabinoid receptor ligands on rat cultured sensory
neurones: implications for antinociception. Neuropharmacology 40:221–232
Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG
(2001b) Structure-activity relationship for the endogenous cannabinoid, anandamide,
and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Br J Pharmacol 132:631–640
Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, Ellington HC (2002)
Pharmacological characterization of the anandamide cyclooxygenase metabolite: pro-
staglandin E2 ethanolamide. J Pharmacol Exp Ther 301:900–907
Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate
capsaicin-induced responses in human skin. Pain 102:283–288
Sagar DR, Smith PA, Millns PJ, Smart D, Kendall DA, Chapman V (2004) TRPV1 and CB(1)
receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dop-
amine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur
J Neurosci 20:175–184
Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M (2001) CB1-cannabinoid
and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn.
Neuroreport 12:3689–3692
Salio C, Doly S, Fischer J, Franzoni M, Conrath M (2002a) Neuronal and astrocytic localiza-
tion of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci
Lett 329:13
Salio C, Fischer J, Franzoni MF, Conrath M (2002b) Pre- and postsynaptic localizations of
the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience
110:755–764